

Michael A Pulsipher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8631892/publications.pdf>

Version: 2024-02-01

189
papers

12,455
citations

38742

50
h-index

28297

105
g-index

198
all docs

198
docs citations

198
times ranked

12166
citing authors

#	ARTICLE	IF	CITATIONS
1	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 439-448.	27.0	3,680
2	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. <i>New England Journal of Medicine</i> , 2012, 367, 1487-1496.	27.0	762
3	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009. <i>New England Journal of Medicine</i> , 2014, 371, 434-446.	27.0	594
4	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	5.2	263
5	Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2009, 113, 3604-3611.	1.4	235
6	Immune reconstitution and survival of 100 SCID patients post–hematopoietic cell transplant: a PIDTC natural history study. <i>Blood</i> , 2017, 130, 2718-2727.	1.4	212
7	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	1.6	185
8	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. <i>Blood</i> , 2015, 125, 3501-3508.	1.4	177
9	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 833.	7.4	177
10	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016, 128, 2561-2567.	1.4	174
11	Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 6175-6184.	7.0	170
12	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	1.4	140
13	Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. <i>Blood</i> , 2009, 114, 2606-2616.	1.4	130
14	Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 704-717.e5.	2.9	128
15	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. <i>Blood</i> , 2018, 132, 1737-1749.	1.4	128
16	Immunogenicity of CAR T cells in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 379-393.	27.6	128
17	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013, 121, 197-206.	1.4	123
18	Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. <i>Blood</i> , 2014, 123, 3655-3663.	1.4	112

#	ARTICLE	IF	CITATIONS
19	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021, 39, 1865-1877.	1.6	111
20	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. <i>Blood</i> , 2014, 123, 2017-2025.	1.4	109
21	Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety considerations for normal pediatric hematopoietic cell donors. <i>Pediatric Blood and Cancer</i> , 2006, 46, 422-433.	1.5	105
22	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <i>Blood</i> , 2010, 116, 4007-4015.	1.4	105
23	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. <i>Journal of Clinical Oncology</i> , 2022, 40, 932-944.	1.6	93
24	NCI, NHLBI/PBMTTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Endocrine Challenges—Thyroid Dysfunction, Growth Impairment, Bone Health, & Reproductive Risks. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1725-1738.	2.0	89
25	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. <i>Blood</i> , 2020, 135, 2094-2105.	1.4	87
26	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418.	4.6	84
27	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	1.4	83
28	Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor T Cells. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 285-295.	2.5	83
29	National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 334-347.	2.0	82
30	Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 935-943.e15.	2.9	82
31	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	5.2	81
32	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 201-210.	2.0	79
33	Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. <i>Blood</i> , 2009, 114, 1429-1436.	1.4	78
34	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. <i>Blood</i> , 2018, 132, 1438-1451.	1.4	78
35	National Cancer Institute—National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Long-Term Organ Damage and Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1573-1584.	2.0	76
36	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71

#	ARTICLE	IF	CITATIONS
37	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
38	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 66-81.	5.0	70
39	Hypogammaglobulinemia due to CAR T cell therapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26914.	1.5	67
40	Myeloid lineage switch following chimeric antigen receptor T cell therapy in a patient with TCF3- <i>ZNF384</i> fusion-positive B-lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27265.	1.5	67
41	Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 552-561.	2.0	66
42	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 1710-1718.	10.7	65
43	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	1.2	65
44	Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. <i>Lancet Haematology</i> , 2015, 2, e367-e375.	4.6	64
45	Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. <i>Blood</i> , 2010, 115, 5097-5101.	1.4	63
46	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	5.2	63
47	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 67-73.	2.0	62
48	Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. <i>Blood</i> , 2019, 134, 304-316.	1.4	62
49	Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring and Novel Chemotherapeutic, Molecular, and Immune Approaches Aimed at Preventing Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 62-71.	2.0	61
50	High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S137-S148.	2.0	60
51	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis. <i>Blood</i> , 2016, 128, 2801-2801.	1.4	58
52	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. <i>Frontiers in Immunology</i> , 2020, 11, 239.	4.8	57
53	Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 880-882.e10.	2.9	54
54	Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. <i>Blood Advances</i> , 2023, 7, 575-585.	5.2	52

#	ARTICLE	IF	CITATIONS
55	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2019, 134, LBA-1-LBA-1.	1.4	51
56	Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1007-1011.	2.0	49
57	Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 379-387.	2.0	49
58	Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies. <i>Blood</i> , 2020, 135, 1287-1298.	1.4	49
59	Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2052-2060.	2.0	48
60	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 1537-1543.	1.6	47
61	A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. <i>Blood</i> , 2007, 110, 4584-4587.	1.4	45
62	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2015, 170, 574-583.	2.5	45
63	Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogeneic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1229-1240.	2.0	44
64	Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1467-1472.	2.0	43
65	Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1422-1428.	2.0	43
66	Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. <i>Journal of Clinical Immunology</i> , 2019, 39, 653-667.	3.8	41
67	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	41
68	Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1313-1321.	2.0	40
69	Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 513-521.	0.8	40
70	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. <i>Haematologica</i> , 2017, 102, 1291-1298.	3.5	38
71	Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
72	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	5.2	37

#	ARTICLE	IF	CITATIONS
73	Beyond the storm " subacute toxicities and late effects in children receiving CAR T cells. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 363-378.	27.6	37
74	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021, 41, 38-50.	3.8	36
75	Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 96-103.	2.0	35
76	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. <i>Haematologica</i> , 2014, 99, 1624-1631.	3.5	33
77	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
78	The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 24-29.	2.0	33
79	NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Etiology and Pathogenesis of Late Effects after HCT Performed in Childhood" Methodologic Challenges. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1428-1435.	2.0	32
80	Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. <i>Journal of Pediatrics</i> , 2016, 178, 164-170.e1.	1.8	32
81	Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 291-299.	2.0	31
82	Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. <i>Blood</i> , 2014, 123, 3504-3511.	1.4	31
83	Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 326-335.	2.0	31
84	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2040-2046.	2.0	29
85	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. <i>Haematologica</i> , 2020, 106, 46-55.	3.5	29
86	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
87	A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft-versus-host disease prophylaxis after allogeneic hematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). <i>British Journal of Haematology</i> , 2009, 147, 691-699.	2.5	27
88	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	4.1	27
89	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 301-306.	2.0	27
90	Race and Ethnicity Influences Collection of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 165-171.	2.0	26

#	ARTICLE	IF	CITATIONS
91	Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. <i>Blood</i> , 2022, 140, 685-705.	1.4	26
92	Impact of Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children with Acute Myelogenous Leukemia beyond First Complete Remission: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1620-1627.	2.0	25
93	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2154-2159.	2.0	25
94	Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1278-1287.	2.4	25
95	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019, 104, 380-391.	3.5	25
96	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
97	Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The UTRH Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1216-1222.	2.0	23
98	European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 514-519.	2.0	21
99	Are CAR T cells better than antibody or HCT therapy in B-ALL?. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 16-24.	2.5	21
100	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1508-1515.	7.2	21
101	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
102	Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival. <i>Blood</i> , 2020, 136, 13-14.	1.4	19
103	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1651-1656.	2.0	18
104	Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. <i>Blood Advances</i> , 2022, 6, 746-749.	5.2	18
105	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
106	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	7.2	16
107	Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1097-1104.e2.	2.9	16
108	Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. <i>Cytotherapy</i> , 2015, 17, 1667-1674.	0.7	15

#	ARTICLE	IF	CITATIONS
109	Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2020, 4, 2158-2162.	5.2	15
110	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.	2.0	14
111	Metabolomic identification of \uparrow -ketoglutaric acid elevation in pediatric chronic graft-versus-host disease. <i>Blood</i> , 2022, 139, 287-299.	1.4	14
112	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , 2016, 57, 1567-1574.	1.3	13
113	Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1523-1530.	2.0	13
114	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
115	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019, 104, 844-854.	3.5	13
116	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838.	2.0	12
117	Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (\geq 60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 165-171.	2.0	12
118	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4980-4991.	5.2	12
119	Advancement of Pediatric Blood and Marrow Transplantation Research in North America: Priorities of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1212-1221.	2.0	11
120	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411.	2.0	11
121	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
122	A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28444.	1.5	11
123	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. <i>Blood Advances</i> , 2020, 4, 706-716.	5.2	11
124	A donor's a person, no matter how small. <i>Blood</i> , 2012, 119, 2705-2706.	1.4	10
125	Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1780-1788.	2.4	10
126	Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 556-561.	2.0	10

#	ARTICLE	IF	CITATIONS
127	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	2.4	10
128	KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 256-256.	1.4	10
129	Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2015, 171, 411-416.	2.5	9
130	Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). <i>Blood</i> , 2013, 122, 543-543.	1.4	9
131	Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. <i>Blood</i> , 2021, 138, 428-428.	1.4	9
132	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	5.2	9
133	KIR-favorable TCR- $\alpha\beta$ /CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. <i>Blood</i> , 2022, 140, 2556-2572.	1.4	9
134	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 402-411.	2.0	8
135	Low rate of subsequent malignant neoplasms following CAR T-cell therapy. <i>Blood Advances</i> , 0, , .	5.2	8
136	Haplo is the new black. <i>Blood</i> , 2014, 124, 675-676.	1.4	7
137	Deficient Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplantation. <i>Frontiers in Immunology</i> , 2016, 7, 250.	4.8	7
138	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
139	Methods and role of minimal residual disease after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 681-690.	2.4	7
140	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 955-964.	2.0	7
141	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 2121-2131.	2.4	7
142	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1747-1756.	2.0	7
143	Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e142-e144.	2.0	7
144	Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. <i>Cancer Immunology Research</i> , 2022, 10, 856-870.	3.4	7

#	ARTICLE	IF	CITATIONS
145	Reduced Intensity for Myelodysplastic Syndrome: Worth the Gamble?. <i>Journal of Clinical Oncology</i> , 2017, 35, 2106-2108.	1.6	6
146	Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 308-313.	2.0	6
147	Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2365-2371.	2.0	6
148	Chimerism versus Minimal Residual Disease Monitoring after Allogeneic Transplantation—When Do We Act and Will Intervention Improve Outcomes?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1461-1462.	2.0	4
149	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	3.5	4
150	Hematopoietic Stem Cell Transplantation. <i>Pediatric Oncology</i> , 2018, , 301-311.	0.5	4
151	Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance. <i>Bone Marrow Transplantation</i> , 2018, 53, 949-959.	2.4	4
152	Advances in hematopoietic cell transplant for the treatment of hematologic malignancies. <i>Current Opinion in Pediatrics</i> , 2019, 31, 3-13.	2.0	4
153	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.	2.0	4
154	Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy. <i>Blood</i> , 2018, 132, 4012-4012.	1.4	4
155	HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia. <i>Blood</i> , 2020, 136, 23-24.	1.4	4
156	Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children’s Oncology Group (COG) AALL0433. <i>Blood</i> , 2014, 124, 684-684.	1.4	4
157	Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	4
158	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor’s Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 603.e1-603.e7.	1.2	4
159	Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. <i>Bone Marrow Transplantation</i> , 2021, 56, 2869-2870.	2.4	3
160	Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3044-3044.	1.6	3
161	Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children’s Oncology Group experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 445-452.	2.4	3
162	Serotherapy as Graft-Versus-Host Disease Prophylaxis in Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia. <i>Frontiers in Pediatrics</i> , 2021, 9, 805189.	1.9	3

#	ARTICLE	IF	CITATIONS
163	Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy. <i>Journal of Clinical Immunology</i> , 2022, 42, 1026-1035.	3.8	3
164	Better BMT for Hurler syndrome on the level?. <i>Blood</i> , 2013, 121, 3785-3787.	1.4	2
165	Long-term outcomes in MPS-IH: throwing stars. <i>Blood</i> , 2015, 125, 2016-2017.	1.4	2
166	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
167	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28574.	1.5	2
168	Continued Role for Radiation in the Conditioning Regimen for Children With ALL. <i>Journal of Clinical Oncology</i> , 2021, 39, 262-264.	1.6	2
169	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 503.e1-503.e8.	1.2	2
170	Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 352.e1-352.e5.	1.2	2
171	Postgrafting Immune Suppression Combined with Nonmyeloablative Conditioning for Transplantation of HLA-Identical Hematopoietic Cell Grafts: Results of a Phase I Study for Treatment of Immunodeficiency Disorders. <i>Blood</i> , 2005, 106, 327-327.	1.4	1
172	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables. <i>Blood</i> , 2010, 116, 3450-3450.	1.4	1
173	A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience. <i>Blood</i> , 2015, 126, 1949-1949.	1.4	1
174	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201. <i>Blood</i> , 2021, 138, 1772-1772.	1.4	1
175	Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTc 1202 Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	1
176	RE: Is G-CSF-mobilized peripheral stem cell harvest harmful?. <i>Pediatric Blood and Cancer</i> , 2007, 48, 596-596.	1.5	0
177	There's more to surviving transplant than remission (commentary on Wood et al., page 499). <i>Pediatric Blood and Cancer</i> , 2011, 57, 359-360.	1.5	0
178	Fishing for complements. <i>Blood</i> , 2016, 127, 957-958.	1.4	0
179	Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation" <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1734.	2.0	0
180	Hematopoietic Cell Transplantation for the Treatment of Patients with Bone Marrow Failure Syndromes. <i>Pediatric Oncology</i> , 2018, , 165-179.	0.5	0

#	ARTICLE	IF	CITATIONS
181	Response Assessment and Postâ€“CAR T-Cell Therapy Management. , 2020, , 113-127.		0
182	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biology of Blood and Marrow Transplantation, 2020, 26, e235-e236.	2.0	0
183	Baseline Symptoms, Female Sex, and Younger Age Are Correlated with Higher Levels of Peri-Collection Pain, Symptoms, and Persistent Discomfort One Year after Related Donor BM and PBSC Donation: An Analysis of the Related Donor Safety Study (RDSafe). Blood, 2014, 124, 3847-3847.	1.4	0
184	Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial.. Journal of Clinical Oncology, 2016, 34, 7052-7052.	1.6	0
185	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. Blood, 2018, 132, 356-356.	1.4	0
186	Hematopoietic stem cell transplantation and cellular therapy. , 2022, , 623-657.		0
187	Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC). Blood, 2020, 136, 42-43.	1.4	0
188	Cortical Thinning and Neuropsychologic Measures Predict CD19 CAR T Cell Therapy-Associated Neurotoxicity. Blood, 2020, 136, 26-27.	1.4	0
189	Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity. Blood, 2020, 136, 36-37.	1.4	0